Abbott Vascular is calling a halt to sales of the Absorb bioresorbable vascular scaffold as of September 14, 2017, attributing the decision to “low commercial sales.” “We pioneered bioresorbable ...
WASHINGTON, DC—Three-year outcomes from the ABSORB II trial, a time point in which the Absorb GT1 bioresorbable vascular scaffold should be degraded, did not result in an improvement in vasomotor tone ...
The Absorb LMS is a learning platform that is business focused. It has numerous functions to better engage learners such as a social aspect, and custom certificates. While it has smartphone apps, the ...
Calgary edtech Absorb Software is set to be acquired by New York’s Welsh, Carson, Anderson & Stowe (WCAS), in a deal that is said to value Absorb at over $630 million CAD ($500 million USD). WCAS has ...
In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent presence of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results